Cumulus Neuroscience Joins Transatlantic Hunt For Alzheimer’s Blood And Digital Biomarkers

Cumulus Neuroscience has been granted £1.2m from Innovate UK to validate AccelADx, an AI-powered, non-invasive Alzheimer’s screening test that combines EEG and tablet-based assessments, as part of a transatlantic study investigating digital and blood-based biomarkers for Alzheimer's dementia.

• Source: Shutterstock

Cumulus Neuroscience announced nearly £1.2m in funding from Innovate UK's Small Business Research Initiative (SBRI) to support ongoing clinical validation of AccelADx, a “breakthrough” screening test for early detection of Alzheimer's dementia.

With an estimated 60 million people living with Alzheimer’s disease today, “Quicker, more accurate ways to diagnose dementia are greatly...

More from R&D

More from Business